BHO Research
BHO
A Real-World Analysis of the Clinical Journey, Diagnosis, and Monitoring Patterns of Patients With Alzheimer Disease by Stage in the United States
September 12, 2025
BHO
Prediction of infusion capacity to deliver Alzheimer’s disease treatments in the United States relative to expected demand
August 29, 2025
BHO
A preliminary economic evaluation of a potential program for the primary prevention of Alzheimer’s disease
August 23, 2025
BHO
Use of Cognitive Screening among Older Adults Who Care for People with Dementia: A National Survey
August 4, 2025
BHO
System readiness and the patient care pathway for Alzheimer’s disease diagnosis and treatment
June 19, 2025
BHO
Estimation of the value-based price of a blood test for Alzheimer’s disease pathology in primary and specialty care in the U.S
June 9, 2025
BHO
The impact of real-world evidence in implementing and optimizing Alzheimer’s disease care
May 9, 2025
BHO
Measuring time saved in Alzheimer’s disease: What is a meaningful slowing of progression?
April 11, 2025
BHO
Demographic and clinical characteristics of initial patients receiving amyloid-targeting treatments in the United States after regulatory approval
March 21, 2025
BHO
Usage patterns of cognitive assessments during Medicare’s Annual Wellness Visit: A national survey
February 21, 2025
BHO
Effects of the Davos Alzheimer’s Collaborative early detection of cognitive impairment program on clinician attitudes, engagement, and confidence
February 4, 2025
BHO
Disparities in Access to Diagnostic Evaluation for Alzheimer’s Disease in Individuals Dually Eligible for Medicare and Medicaid: A Modeling Study
January 24, 2025
BHO
American’s overall and equity-based societal valuation of a disease-modifying Alzheimer’s treatment: Results from a discrete choice experiment
January 1, 2025
BHO
Real-world diagnostic, referral, and treatment patterns in early Alzheimer’s disease among community-based practices in the United States
November 29, 2024
BHO
Expected wait times for access to a disease-modifying Alzheimer’s treatment in England: A modelling study
November 6, 2024
BHO
Current Capacity for Diagnosing Alzheimer’s Disease in Germany and Implications for Wait Times
October 8, 2024
BHO
Considerations for widespread implementation of blood‐based biomarkers of Alzheimer’s disease
October 6, 2024
BHO
Recommendations for clinical implementation of blood‐based biomarkers for Alzheimer’s disease
October 1, 2024
BHO
Estimates of Current Capacity for Diagnosing Alzheimer’s Disease in Sweden and the Need to Expand Specialist Numbers – September 15, 2024
September 15, 2024
BHO
Implications of treatment duration and frequency for value and cost-effective price of Alzheimer treatmentsImplications of treatment duration and frequency for value and cost-effective price of Alzheimer treatments
July 22, 2024
BHO
Acceptable performance of blood biomarker tests of amyloid pathology — recommendations from the Global CEO Initiative on Alzheimer’s Disease
June 12, 2024
BHO
Medical Costs and Caregiver Burden of Delivering Disease-Modifying Alzheimer’s Treatments with Different Duration and Route of Administration.
May 7, 2024
BHO
State Department of Motor Vehicles Reporting Mandates of Dementia Diagnoses and Dementia Underdiagnosis
April 25, 2024
BHO
Economic Impact of Progression from Mild Cognitive Impairment to Alzheimer Disease in the United States
April 2, 2024
BHO
Estimated Investment Need to Increase England’s Capacity to Diagnose Eligibility for an Alzheimer’s Treatment to G7 Average Capacity Levels
February 7, 2024
BHO
A chance to prevent Alzheimer’s disease sooner than you think
February 2, 2024
BHO
Health Economic Considerations in the Deployment of an Alzheimer’s Prevention Therapy
January 30, 2024
BHO
Focusing on Earlier Management of Alzheimer Disease: Expert Opinion Based on a Modified Nominal Group Technique
January 29, 2024
BHO
Estimates of Current Capacity for Diagnosing Alzheimer’s Disease in Sweden and the Need to Expand Specialist Numbers – January 11, 2024
January 11, 2024
BHO
Detection Rates of Mild Cognitive Impairment in Primary Care for the United States Medicare Population
January 11, 2024
BHO
Projected Savings to Canadian Provincial Budgets from Reduced Long-Term Care Home Utilization Due to a Disease-Modifying Alzheimer’s Treatment
January 11, 2024
BHO
The age-specific comorbidity burden of mild cognitive impairment: a US claims database study
December 6, 2023
BHO
Expected wait times for access to a disease-modifying Alzheimer’s treatment in England: A modelling study
November 6, 2023
BHO
Detection Rates of Mild Cognitive Impairment in Primary Care for the United States Medicare Population
October 24, 2023
BHO
Estimates of Current Capacity for Diagnosing Alzheimer’s Disease in Sweden and the Need to Expand Specialist Numbers – September 15, 2023
September 15, 2023
BHO
A Literature Review on the Burden of Alzheimer’s Disease on Care Partners
September 12, 2023
BHO
Expected and diagnosed rates of mild cognitive impairment and dementia in the U.S. Medicare population: observational analysis
July 22, 2023
BHO
Blood-based biomarkers for Alzheimer’s disease: Current state and future use in a transformed global healthcare landscape
June 8, 2023
BHO
Preparedness of China’s health care system to provide access to a disease-modifying Alzheimer’s treatment
June 6, 2023
BHO
Expanding the use of brief cognitive assessments to detect suspected early-stage cognitive impairment in primary care
April 19, 2023
BHO
A framework for addressing Alzheimer’s disease: Without a frame, the work has no aim
December 8, 2022
BHO
Improving community health-care systems’ early detection of cognitive decline and dementia
October 31, 2022
BHO
Blood Biomarkers from Research Use to Clinical Practice: What Must Be Done? A Report from the EU/US CTAD Task Force
October 16, 2022
BHO
Projected Ontario budget savings from reduced long-term care utilization due to a disease-modifying Alzheimer’s treatment
September 14, 2022
BHO
Preparedness of the Brazilian health-care system to provide access to a disease-modifying Alzheimer’s disease treatment
September 5, 2022
BHO
Designing the next-generation clinical carepathway for Alzheimer’s disease
August 19, 2022
BHO
From Trials to Practice: Are We Ready for a Disease-Modifying Treatment?
March 3, 2022
BHO
Projecting the long-term societal value of a disease-modifying treatment for Alzheimer’s disease in the United States
February 9, 2022
BHO
Why would Canada have the longest wait times for an Alzheimer’s treatment among the G7 countries?
January 31, 2022
BHO
Association of Adverse Events in Opioid Addiction Treatment With Quality Measure for Continuity of Pharmacotherapy
January 25, 2022
BHO
Developing a pathway to support the appropriate, affordable, and widespread use of effective Alzheimer’s prevention drugs
January 18, 2022
BHO
Expected wait times for access to a disease-modifying Alzheimer’s treatment in the United States
September 27, 2021
BHO
Memory care approaches to better leverage capacity of dementia specialists: a narrative synthesis
May 10, 2021
BHO
Is Korea Prepared for an Alzheimer’s Disease-Modifying Therapy? Assessing the Korean Healthcare System Infrastructure and the Effect of Blood-Based Biomarker Tests
February 4, 2021
BHO
Projection of budgetary savings to US state Medicaid programs from reduced nursing home use due to an Alzheimer’s disease treatment
January 1, 2021
BHO
Assessing the Preparedness of the Taiwanese Healthcare System Infrastructure for an Alzheimer’s Treatment
January 1, 2021
BHO
How Much Value Would a Treatment for Alzheimer’s Disease Offer? Cost-Effectiveness Thresholds for Pricing a Disease-Modifying Therapy
January 1, 2020
BHO
Blood-based biomarkers for Alzheimer’s pathology and the diagnostic process for a disease-modifying treatment: Projecting the impact on the cost and wait times
January 1, 2020
BHO
Estimating minimal clinically important differences for two scales in patients with chronic traumatic brain injury
January 1, 2020
BHO
Implications of Alzheimer’s Treatment for Organization and Payment of Medical Practices in Canada
January 1, 2020
BHO
Implications of Alzheimer’s Treatment for Organization and Payment of Medical Practices in the United States
January 1, 2020
BHO
Assessing the Preparedness of the Korean Healthcare System Infrastructure for an Alzheimer’s Treatment
January 1, 2020
BHO
Implications of Alzheimer’s Treatment for OrganizationAnd Payment of Medical Practices in the Eu-5 Countries
January 1, 2020
BHO
Assessing the Preparedness of the Australian Health Care System Infrastructure for an Alzheimer’s Disease-Modifying Therapy
September 21, 2019
BHO
The Potential Emergence of Disease-Modifying Treatments for Alzheimer Disease: The Role of Primary Care in Managing the Patient Journey
January 1, 2019
BHO
The Predicted Long-Term Benefits of Ensuring Timely Treatment and Medication Adherence in Early Schizophrenia
January 1, 2019
BHO
Assessing the Preparedness of the Canadian Health Care System Infrastructure for an Alzheimer’s Treatment
January 1, 2019
BHO
Assessing the Preparedness of the Japanese Health Care System Infrastructure for an Alzheimer’s Treatment
January 1, 2019
BHO
Assessing the Preparedness of the Canadian Health Care System Infrastructure for an Alzheimer’s Treatment
January 1, 2019
BHO
Potential Benefits to Patients and Payers From Increased Measurement of Antipsychotic Plasma Levels in the Management of Schizophrenia
January 1, 2018
BHO
Simulated long-term outcomes of early use of long-acting injectable antipsychotics in early schizophrenia
January 1, 2018
BHO
Evidence for Misspecification of a Nationally Used Quality Measure for Substance Use Treatment
January 1, 2018
BHO
Assessing the Preparedness of the Health Care System Infrastructure in Six European Countries for an Alzheimer’s Treatment
January 1, 2018
BHO
The Role of Antipsychotic Plasma Levels in the Treatment of Schizophrenia
January 1, 2017
BHO
Improving Antipsychotic Adherence Among Patients With Schizophrenia: Savings for States
January 1, 2015
